Published in J Pharm Pharmacol on February 01, 1999
Albendazole treatment in cystic echinococcosis: pharmacokinetics and clinical efficacy of two different aqueous formulations. Parasitol Res (2008) 1.02
Relative bioavailability of three newly developed albendazole formulations: a randomized crossover study with healthy volunteers. Antimicrob Agents Chemother (2004) 0.89
Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells. Oncotarget (2015) 0.81
In vivo evaluation of modified gum karaya as a carrier for improving the oral bioavailability of a poorly water-soluble drug, nimodipine. AAPS PharmSciTech (2002) 0.78
Solid Dispersion Matrix Tablet Comprising Indomethacin-PEG-HPMC Fabricated with Fusion and Mold Technique. Indian J Pharm Sci (2009) 0.77
Population pharmacokinetic modeling of itraconazole and hydroxyitraconazole for oral SUBA-itraconazole and sporanox capsule formulations in healthy subjects in fed and fasted states. Antimicrob Agents Chemother (2015) 0.77
Characterization of indomethacin release from polyethylene glycol tablet fabricated with mold technique. Indian J Pharm Sci (2010) 0.75
Influence of Hydroxypropyl Methylcellulose on Metronidazole Crystallinity in Spray-Congealed Polyethylene Glycol Microparticles and Its Impact with Various Additives on Metronidazole Release. AAPS PharmSciTech (2015) 0.75
FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70
Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76
Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation (1996) 7.29
The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89
Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92
Abdominal organ cluster transplantation for the treatment of upper abdominal malignancies. Ann Surg (1989) 5.78
Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70
Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90
Biological and chemical detection of trichothecene mycotoxins of Fusarium species. Appl Microbiol (1973) 4.37
A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29
Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21
Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18
Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16
Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12
ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol (1994) 4.09
Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. J Cell Biol (1996) 4.06
Baboon-to-human liver transplantation. Lancet (1993) 4.01
Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85
Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis (2008) 3.77
Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73
Transplantation of multiple abdominal viscera. JAMA (1989) 3.59
Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
IN VITRO IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 ON HUMAN T LYMPHOCYTE ALLOACTIVATION. Surg Res Commun (1987) 3.46
Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40
Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31
Race-specific HIV-1 disease-modifying effects associated with CCR5 haplotypes. Proc Natl Acad Sci U S A (1999) 3.21
Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18
Liver transplantation before 1 year of age. J Pediatr (1987) 3.15
In Vitro Immunosuppressive Effects of FK506 in Combination With Other Drugs. Transplant Proc (1988) 3.15
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Biliary tract complications in human orthotopic liver transplantation. Transplantation (1987) 2.95
Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J Cell Biol (2000) 2.94
Perturbation of cell adhesion and microvilli formation by antisense oligonucleotides to ERM family members. J Cell Biol (1994) 2.93
Experience in 1,000 liver transplants under cyclosporine-steroid therapy: a survival report. Transplant Proc (1988) 2.87
Expression cloning of the human IL-3 receptor cDNA reveals a shared beta subunit for the human IL-3 and GM-CSF receptors. Cell (1991) 2.84
The use of FK-506 for small intestine allotransplantation. Inhibition of acute rejection and prevention of fatal graft-versus-host disease. Transplantation (1990) 2.79
Demonstration of granulopoietic factor(s) in the plasma of nude mice transplanted with a human lung cancer and in the tumor tissue. Blood (1977) 2.76
THE IMMUNOSUPPRESSIVE EFFECTS OF FR 900506 IN RATS RECEIVING HETEROTOPIC CARDIAC ALLOGRAFTS. Surg Res Commun (1987) 2.75
Development and differences of intestinal flora in the neonatal period in breast-fed and bottle-fed infants. Pediatrics (1983) 2.71
Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/.NO through a radical reaction. Biochemistry (1993) 2.70
Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506. Lancet (1990) 2.66
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Suppression of allograft rejection with FK506. I. Prolonged cardiac and liver survival in rats following short-course therapy. Transplantation (1990) 2.59
Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK 506. Transplant Proc (1991) 2.59
JAK2 associates with the beta c chain of the receptor for granulocyte-macrophage colony-stimulating factor, and its activation requires the membrane-proximal region. Mol Cell Biol (1994) 2.55
A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc (1991) 2.49
Pharmacokinetics of FK 506: preclinical and clinical studies. Transplant Proc (1990) 2.48
FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology (2001) 2.46
Comparative toxicology of trichothec mycotoxins: inhibition of protein synthesis in animal cells. J Biochem (1973) 2.45
Radixin is a novel member of the band 4.1 family. J Cell Biol (1991) 2.40
Upper abdominal exenteration with liver replacement: a modification of the "cluster" procedure. Transplant Proc (1990) 2.40
Hepatotrophic effects of FK506 in dogs. Transplantation (1991) 2.39
Liver transplantation across ABO blood groups. Surgery (1986) 2.39
Toxicological approaches to the metabolites of Fusaria. V. Neosolaniol, T-2 toxin and butenolide, toxic metabolites of Fusarium sporotrichioides NRRL 3510 and Fusarium poae 3287. Jpn J Exp Med (1972) 2.37
Toxicology of FK-506 in the Lewis rat. Transplant Proc (1987) 2.37
The antibody crossmatch in liver transplantation. Surgery (1986) 2.33
The incidence, timing, and management of biliary tract complications after orthotopic liver transplantation. Ann Surg (1994) 2.32
The effects of FK 506 on renal function after liver transplantation. Transplant Proc (1990) 2.31
Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31
Animal research in liver transplantation with special reference to the dog. Semin Liver Dis (1985) 2.28
The hepatotropic influence of cyclosporine. Surgery (1990) 2.27
Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. Transplant Proc (1991) 2.26
Assessment of five-year experience with abdominal organ cluster transplantation. J Am Coll Surg (1995) 2.25
Retention of multilineage differentiation potential of mesenchymal cells during proliferation in response to FGF. Biochem Biophys Res Commun (2001) 2.24
Increased MR signal intensity due to cervical myelopathy. Analysis of 29 surgical cases. J Neurosurg (1991) 2.22
Three years clinical experience with intestinal transplantation. J Am Coll Surg (1994) 2.20
Overexpression of occludin, a tight junction-associated integral membrane protein, induces the formation of intracellular multilamellar bodies bearing tight junction-like structures. J Cell Sci (1996) 2.20
Induction of liver, heart, and multivisceral graft acceptance with a short course of FK 506. Transplant Proc (1990) 2.15
Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation (1993) 2.14
Presenilin-1 mutations downregulate the signalling pathway of the unfolded-protein response. Nat Cell Biol (1999) 2.14
FK506 suppression of heart and liver allograft rejection. II: The induction of graft acceptance in rats. Transplantation (1990) 2.13
Complications of venous reconstruction in human orthotopic liver transplantation. Ann Surg (1987) 2.11
The human REV1 gene codes for a DNA template-dependent dCMP transferase. Nucleic Acids Res (1999) 2.10
The side effects of FK 506 in humans. Transplant Proc (1990) 2.08
Use of quantitative competitive PCR to measure Epstein-Barr virus genome load in the peripheral blood of pediatric transplant patients with lymphoproliferative disorders. J Clin Microbiol (1997) 2.05
Should the cement mantle around the femoral component be thick or thin? J Bone Joint Surg Br (2003) 2.05
Randomised trialomania? The multicentre liver transplant trials of tacrolimus. Lancet (1995) 2.04
Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells. Br J Cancer (2004) 2.03
How enzymes adapt: lessons from directed evolution. Trends Biochem Sci (2001) 2.03
Augmentation of rat liver regeneration by FK 506 compared with cyclosporin. Lancet (1989) 2.01
Low flow venovenous bypasses in small dogs and pediatric patients undergoing replacement of the liver. Surg Gynecol Obstet (1986) 2.00
Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg (1998) 1.99
Acute infectious mononucleosis. CD30 (Ki-1) antigen expression and histologic correlations. Am J Clin Pathol (1990) 1.99
Pathology of human intestinal transplantation. Gastroenterology (1996) 1.98
Toxicological approaches to the metabolites of Fusaria. VI. Vomiting factor from moldy corn infected with Fusarium spp. Jpn J Exp Med (1974) 1.95
Delayed neuronal death in the CA1 pyramidal cell layer of the gerbil hippocampus following transient ischemia is apoptosis. J Neurosci (1995) 1.95
FK 506 in steroid-resistant focal sclerosing glomerulonephritis of childhood. Lancet (1990) 1.94
Analysis of donor criteria for the prediction of outcome in clinical liver transplantation. Transplant Proc (1987) 1.90
Orthotopic liver transplantation for primary sclerosing cholangitis. Ann Surg (1988) 1.89
Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. Transplant Proc (1991) 1.89
Concentration of an integral membrane protein, CD43 (leukosialin, sialophorin), in the cleavage furrow through the interaction of its cytoplasmic domain with actin-based cytoskeletons. J Cell Biol (1993) 1.88
Logistics and technique for combined hepatic-intestinal retrieval. Ann Surg (1992) 1.85
The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation (1992) 1.83
Endotoxaemia, pulmonary complications, and thrombocytopenia in liver transplantation. Lancet (1989) 1.82
Corrective treatment and anatomic considerations for laparoscopic cholecystectomy injuries. J Am Coll Surg (1994) 1.81
A human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: induction and maintenance therapy. Am J Transplant (2009) 1.81
Pathologic observations in human allograft recipients treated with FK 506. Transplant Proc (1990) 1.80
Monitoring and treatment of intestinal allograft rejection in humans. Transplant Proc (1993) 1.78
Diffuse pachymeningeal hyperintensity and subdural effusion/hematoma detected by fluid-attenuated inversion recovery MR imaging in patients with spontaneous intracranial hypotension. AJNR Am J Neuroradiol (2008) 1.77